Daxor Corporation (NASDAQ: DXR) Stock Competitors & Peer Comparison
See DXR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DXR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $8.53 | -2.18% | 49.3M | 6.87 | $1.23 | N/A |
| ISRG | $450.04 | -2.28% | 156B | 46.78 | $9.62 | N/A |
| BDX | $212.61 | -1.23% | 57.9B | 16.35 | $13.00 | +1.86% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +1.86% |
| MDLN | $40.91 | +0.49% | 35.9B | 29.98 | $1.36 | N/A |
| RMD | $234.11 | -0.69% | 32.9B | 20.31 | $11.53 | +1.06% |
| WST | $412.55 | -0.07% | 28.7B | 44.86 | $9.20 | +0.22% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.08 | -0.39% | 15.3B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.86% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
DXR vs ISRG Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ISRG has a market cap of 156B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ISRG trades at $450.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ISRG's P/E ratio is 46.78. In terms of profitability, DXR's ROE is +0.13%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, DXR is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
DXR vs BDX Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, BDX has a market cap of 57.9B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while BDX trades at $212.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas BDX's P/E ratio is 16.35. In terms of profitability, DXR's ROE is +0.13%, compared to BDX's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
DXR vs BDXA Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas BDXA's P/E ratio is 45.70. In terms of profitability, DXR's ROE is +0.13%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
DXR vs MDLN Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, MDLN has a market cap of 35.9B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while MDLN trades at $40.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas MDLN's P/E ratio is 29.98. In terms of profitability, DXR's ROE is +0.13%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
ResMed Inc. (NYSE: RMD)
DXR vs RMD Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, RMD has a market cap of 32.9B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while RMD trades at $234.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas RMD's P/E ratio is 20.31. In terms of profitability, DXR's ROE is +0.13%, compared to RMD's ROE of +0.25%. Regarding short-term risk, DXR is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for DXR.Check RMD's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
DXR vs WST Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, WST has a market cap of 28.7B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while WST trades at $412.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas WST's P/E ratio is 44.86. In terms of profitability, DXR's ROE is +0.13%, compared to WST's ROE of +0.21%. Regarding short-term risk, DXR is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for DXR.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
DXR vs HOLX Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.13%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
DXR vs SOLV Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, SOLV has a market cap of 15.3B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while SOLV trades at $90.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas SOLV's P/E ratio is 12.69. In terms of profitability, DXR's ROE is +0.13%, compared to SOLV's ROE of +0.03%. Regarding short-term risk, DXR is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for DXR.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
DXR vs BDXB Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.13%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
DXR vs BAX Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, BAX has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while BAX trades at $26.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas BAX's P/E ratio is 12.70. In terms of profitability, DXR's ROE is +0.13%, compared to BAX's ROE of -0.12%. Regarding short-term risk, DXR is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
DXR vs COO Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, COO has a market cap of 12.1B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while COO trades at $63.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas COO's P/E ratio is 13.94. In terms of profitability, DXR's ROE is +0.13%, compared to COO's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for DXR.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
DXR vs RGEN Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, RGEN has a market cap of 11.1B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while RGEN trades at $173.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas RGEN's P/E ratio is 96.66. In terms of profitability, DXR's ROE is +0.13%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, DXR is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
DXR vs AVTR Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, AVTR has a market cap of 10.6B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while AVTR trades at $15.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas AVTR's P/E ratio is 18.32. In terms of profitability, DXR's ROE is +0.13%, compared to AVTR's ROE of +0.06%. Regarding short-term risk, DXR is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
DXR vs ATR Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ATR has a market cap of 9.1B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ATR trades at $144.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ATR's P/E ratio is 25.19. In terms of profitability, DXR's ROE is +0.13%, compared to ATR's ROE of +0.10%. Regarding short-term risk, DXR is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
DXR vs BLCO Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, BLCO has a market cap of 7.6B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while BLCO trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas BLCO's P/E ratio is 32.88. In terms of profitability, DXR's ROE is +0.13%, compared to BLCO's ROE of -0.02%. Regarding short-term risk, DXR is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
DXR vs TFX Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, TFX has a market cap of 6.6B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while TFX trades at $155.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas TFX's P/E ratio is 17.76. In terms of profitability, DXR's ROE is +0.13%, compared to TFX's ROE of +0.10%. Regarding short-term risk, DXR is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
DXR vs MMSI Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, MMSI has a market cap of 5.3B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while MMSI trades at $87.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas MMSI's P/E ratio is 22.46. In terms of profitability, DXR's ROE is +0.13%, compared to MMSI's ROE of +0.10%. Regarding short-term risk, DXR is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
DXR vs ICUI Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ICUI trades at $182.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ICUI's P/E ratio is 22.74. In terms of profitability, DXR's ROE is +0.13%, compared to ICUI's ROE of +0.03%. Regarding short-term risk, DXR is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
DXR vs NVST Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, NVST has a market cap of 4.1B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while NVST trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas NVST's P/E ratio is 17.56. In terms of profitability, DXR's ROE is +0.13%, compared to NVST's ROE of +0.21%. Regarding short-term risk, DXR is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
DXR vs PLSE Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, PLSE has a market cap of 4B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while PLSE trades at $55.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas PLSE's P/E ratio is -46.71. In terms of profitability, DXR's ROE is +0.13%, compared to PLSE's ROE of -0.78%. Regarding short-term risk, DXR is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
Stevanato Group S.p.A. (NYSE: STVN)
DXR vs STVN Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while STVN trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas STVN's P/E ratio is 20.47. In terms of profitability, DXR's ROE is +0.13%, compared to STVN's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
AtriCure, Inc. (NASDAQ: ATRC)
DXR vs ATRC Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ATRC trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ATRC's P/E ratio is 1747.20. In terms of profitability, DXR's ROE is +0.13%, compared to ATRC's ROE of +0.03%. Regarding short-term risk, DXR is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
DXR vs XRAY Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while XRAY trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas XRAY's P/E ratio is 6.78. In terms of profitability, DXR's ROE is +0.13%, compared to XRAY's ROE of -0.09%. Regarding short-term risk, DXR is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
DXR vs BLFS Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas BLFS's P/E ratio is 37.49. In terms of profitability, DXR's ROE is +0.13%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, DXR is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
DXR vs LMAT Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while LMAT trades at $79.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas LMAT's P/E ratio is 29.05. In terms of profitability, DXR's ROE is +0.13%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, DXR is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
DXR vs AZTA Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, AZTA has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while AZTA trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas AZTA's P/E ratio is 96.38. In terms of profitability, DXR's ROE is +0.13%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, DXR is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
DXR vs KMTS Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, KMTS has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while KMTS trades at $29.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas KMTS's P/E ratio is -11.15. In terms of profitability, DXR's ROE is +0.13%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
DXR vs STAA Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while STAA trades at $23.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas STAA's P/E ratio is 41.88. In terms of profitability, DXR's ROE is +0.13%, compared to STAA's ROE of +0.00%. Regarding short-term risk, DXR is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
DXR vs ATRI Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.13%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
DXR vs ANGO Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ANGO has a market cap of 508.4M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ANGO trades at $12.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ANGO's P/E ratio is -31.00. In terms of profitability, DXR's ROE is +0.13%, compared to ANGO's ROE of -0.19%. Regarding short-term risk, DXR is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
DXR vs MMEDV Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas MMEDV's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.13%, compared to MMEDV's ROE of N/A. Regarding short-term risk, DXR is less volatile compared to MMEDV. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MMEDV's competition here
Embecta Corp. (NASDAQ: EMBC)
DXR vs EMBC Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, EMBC has a market cap of 364.3M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while EMBC trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas EMBC's P/E ratio is 2.47. In terms of profitability, DXR's ROE is +0.13%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, DXR is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
DXR vs SMTI Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, SMTI has a market cap of 290.9M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while SMTI trades at $31.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas SMTI's P/E ratio is -527.67. In terms of profitability, DXR's ROE is +0.13%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, DXR is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
DXR vs OSUR Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, OSUR has a market cap of 229.7M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while OSUR trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas OSUR's P/E ratio is -4.83. In terms of profitability, DXR's ROE is +0.13%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, DXR is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
DXR vs PDEX Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, PDEX has a market cap of 223.6M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while PDEX trades at $69.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas PDEX's P/E ratio is 19.14. In terms of profitability, DXR's ROE is +0.13%, compared to PDEX's ROE of +0.26%. Regarding short-term risk, DXR is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
DXR vs UTMD Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, UTMD has a market cap of 207.6M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while UTMD trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas UTMD's P/E ratio is 21.56. In terms of profitability, DXR's ROE is +0.13%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
DXR vs NNNN Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, NNNN has a market cap of 166.8M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while NNNN trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas NNNN's P/E ratio is 25.33. In terms of profitability, DXR's ROE is +0.13%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, DXR is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
DXR vs KRMD Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while KRMD trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas KRMD's P/E ratio is -79.00. In terms of profitability, DXR's ROE is +0.13%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, DXR is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
DXR vs STXS Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, STXS has a market cap of 105.2M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while STXS trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas STXS's P/E ratio is -6.18. In terms of profitability, DXR's ROE is +0.13%, compared to STXS's ROE of -1.33%. Regarding short-term risk, DXR is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
DXR vs AKYA Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.13%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check AKYA's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
DXR vs POCI Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, POCI has a market cap of 55.7M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while POCI trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas POCI's P/E ratio is -11.04. In terms of profitability, DXR's ROE is +0.13%, compared to POCI's ROE of -0.24%. Regarding short-term risk, DXR is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
SkyAI, Inc. (NASDAQ: STSS)
DXR vs STSS Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas STSS's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.13%, compared to STSS's ROE of -0.99%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
DXR vs OMIC Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.13%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
DXR vs IGAP Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.13%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, DXR is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
DXR vs HBIO Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, HBIO has a market cap of 42.2M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while HBIO trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas HBIO's P/E ratio is -25.72. In terms of profitability, DXR's ROE is +0.13%, compared to HBIO's ROE of -1.30%. Regarding short-term risk, DXR is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
DXR vs NEPH Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, NEPH has a market cap of 34.2M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while NEPH trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas NEPH's P/E ratio is 52.50. In terms of profitability, DXR's ROE is +0.13%, compared to NEPH's ROE of +0.17%. Regarding short-term risk, DXR is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
DXR vs ZJYL Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ZJYL has a market cap of 33M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ZJYL trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ZJYL's P/E ratio is 28.80. In terms of profitability, DXR's ROE is +0.13%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
DXR vs SDC Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.13%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
DXR vs MLSS Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, MLSS has a market cap of 27.8M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while MLSS trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas MLSS's P/E ratio is -6.14. In terms of profitability, DXR's ROE is +0.13%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
Invacare Corporation (NYSE: IVC)
DXR vs IVC Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.13%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
DXR vs RVP Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, RVP has a market cap of 16.6M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while RVP trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas RVP's P/E ratio is -4.62. In terms of profitability, DXR's ROE is +0.13%, compared to RVP's ROE of -0.05%. Regarding short-term risk, DXR is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
DXR vs BNGO Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, BNGO has a market cap of 14.5M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while BNGO trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas BNGO's P/E ratio is -0.41. In terms of profitability, DXR's ROE is +0.13%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, DXR is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for DXR.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
DXR vs FEMY Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, FEMY has a market cap of 12M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while FEMY trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas FEMY's P/E ratio is -0.32. In terms of profitability, DXR's ROE is +0.13%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, DXR is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
DXR vs RGNT Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, RGNT has a market cap of 9.2M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while RGNT trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas RGNT's P/E ratio is -0.53. In terms of profitability, DXR's ROE is +0.13%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
Lucyd, Inc (NASDAQ: LUCY)
DXR vs LUCY Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, LUCY has a market cap of 7.5M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while LUCY trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas LUCY's P/E ratio is -0.67. In terms of profitability, DXR's ROE is +0.13%, compared to LUCY's ROE of -1.03%. Regarding short-term risk, DXR is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
DXR vs NSTG Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.13%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
DXR vs CUPR Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, CUPR has a market cap of 4.7M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while CUPR trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas CUPR's P/E ratio is -1.27. In terms of profitability, DXR's ROE is +0.13%, compared to CUPR's ROE of -0.85%. Regarding short-term risk, DXR is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check CUPR's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
DXR vs POAI Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas POAI's P/E ratio is -0.38. In terms of profitability, DXR's ROE is +0.13%, compared to POAI's ROE of -21.19%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
DXR vs MHUA Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.13%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for DXR.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
DXR vs GMVD Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.13%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
DXR vs GMVDW Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.13%, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
DXR vs NXGL Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while NXGL trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas NXGL's P/E ratio is -5.06. In terms of profitability, DXR's ROE is +0.13%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
DXR vs AVGR Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.13%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
DXR vs NXGLW Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, NXGLW has a market cap of 395.5K. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.13%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, DXR is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
DXR vs LUCYW Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.13%, compared to LUCYW's ROE of -1.03%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
DXR vs ATRS Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.13%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
DXR vs IVTY Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas IVTY's P/E ratio is -3.80. In terms of profitability, DXR's ROE is +0.13%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
DXR vs HRC Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.13%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
Apria, Inc. (NASDAQ: APR)
DXR vs APR Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.13%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for DXR.Check APR's competition here
Analogic Corporation (NASDAQ: ALOG)
DXR vs ALOG Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas ALOG's P/E ratio is 40.93. In terms of profitability, DXR's ROE is +0.13%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for DXR.Check ALOG's competition here
IntriCon Corporation (NASDAQ: IIN)
DXR vs IIN Comparison November 2026
Daxor Corporation (NASDAQ: DXR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 49.3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $8.53 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.87, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.13%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for DXR.Check IIN's competition here